Evaluation of Receptor Activator Nuclear Kappa B Ligand and Osteoprotegerin Levels in Patients with Osteoporosis and Bronchiectasis

Abstract

Kemal Güleç, Sevgi Pekcan, Beray Selver Eklioğlu, Asli Imran Yilmaz, Gökçen Ünal, Sevil Kurban, Hanife Tuğçe Çağlar, Fatih Ercan, Suat Savaş, Fatma Nur Ayman and Muhammed Burak Selver

Objective: Bronchiectasis is a condition characterized by irreversible abnormal dilation and anatomic breakdown of the bronchial tree. In our study, we aimed to understand the causes of osteoporosis at molecular levels and to investigate the usefulness of RANKL and OPG levels as markers in early diagnosis and follow-up of osteoporosis, RANKL inhibitors in the treatment of osteoporosis.

Materials and Methods: 30 non-cystic fibrosis bronchiectasis patients were diagnosed with osteoporosis with DEXA and applied to the Pediatrics Chest Diseases Department of Necmettin Erbakan University Faculty of Medicine between June 2015 and June 2016 were included in our study. BMD values were determined by DEXA and QUS in the patient group and only QUS in the control group.

Results: In the patient group 56.6% (n: 17) were male, and 43.4% (n: 13) were. There was no statistically significant difference between RANKL, OPG, RANKL / OPG ratios, BALP, OST, and NTX values between the patient and control group (p> 0.05). The median serum Ca level was 9.51 (IQC: 0.74) in the patient group and 9.75 (IQC: 0.47) in the control group, there was a statistically significant difference between them (p = 0.003). There was a strong positive correlation between QUS z scores and DEXA z scores in the patient group (p = 0.008).

Conclusion: In conclusion, we could not pinpoint the role of RANK / RANKL / OPG in the pathogenesis of osteoporosis in patients with non-cystic fibrosis bronchiectasis. However, we think it is appropriate to conduct studies on a wider series on this topic.

PDF